Details for Patent: 8,741,929
✉ Email this page to a colleague
Which drugs does patent 8,741,929 protect, and when does it expire?
Patent 8,741,929 protects REVLIMID and is included in one NDA.
This patent has thirty-three patent family members in twenty-five countries.
Summary for Patent: 8,741,929
| Title: | Methods using 3-(4-amino-1-oxo-1,3-dihydro-isoindol-2-yl)-piperidine-2,6-dione for treatment of mantle cell lymphomas |
| Abstract: | Methods of treating, preventing or managing mantle cell lymphomas are disclosed. The methods encompass the administration of an immunomodulatory compound of the invention known as Revlimid.RTM. or lenalidomide. The invention further relates to methods of treatment using this compound with chemotherapy, radiation therapy, hormonal therapy, biological therapy or immunotherapy. Pharmaceutical compositions and single unit dosage forms suitable for use in the methods of the invention are also disclosed. |
| Inventor(s): | Zeldis; Jerome B. (Princeton, NJ) |
| Assignee: | Celgene Corporation (Summit, NJ) |
| Application Number: | 12/621,502 |
| Patent Litigation and PTAB cases: | See patent lawsuits and PTAB cases for patent 8,741,929 |
|
Patent Claim Types: see list of patent claims | Use; Delivery; Dosage form; |
Drugs Protected by US Patent 8,741,929
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Patented / Exclusive Use | Submissiondate |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Bristol Myers Squibb | REVLIMID | lenalidomide | CAPSULE;ORAL | 021880-005 | Dec 21, 2011 | AB | RX | Yes | No | ⤷ Try a Trial | ⤷ Try a Trial | USE OF REVLIMID (LENALIDOMIDE) FOR THE TREATMENT OF PATIENTS WITH MANTLE CELL LYMPHOMA WHOSE DISEASE HAS RELAPSED OR PROGRESSED AFTER TWO PRIOR THERAPIES, ONE OF WHICH INCLUDED BORTEZOMIB | ⤷ Try a Trial | |||
| Bristol Myers Squibb | REVLIMID | lenalidomide | CAPSULE;ORAL | 021880-001 | Dec 27, 2005 | AB | RX | Yes | No | ⤷ Try a Trial | ⤷ Try a Trial | USE OF REVLIMID (LENALIDOMIDE) FOR THE TREATMENT OF PATIENTS WITH MANTLE CELL LYMPHOMA WHOSE DISEASE HAS RELAPSED OR PROGRESSED AFTER TWO PRIOR THERAPIES, ONE OF WHICH INCLUDED BORTEZOMIB | ⤷ Try a Trial | |||
| Bristol Myers Squibb | REVLIMID | lenalidomide | CAPSULE;ORAL | 021880-002 | Dec 27, 2005 | AB | RX | Yes | No | ⤷ Try a Trial | ⤷ Try a Trial | USE OF REVLIMID (LENALIDOMIDE) FOR THE TREATMENT OF PATIENTS WITH MANTLE CELL LYMPHOMA WHOSE DISEASE HAS RELAPSED OR PROGRESSED AFTER TWO PRIOR THERAPIES, ONE OF WHICH INCLUDED BORTEZOMIB | ⤷ Try a Trial | |||
| Bristol Myers Squibb | REVLIMID | lenalidomide | CAPSULE;ORAL | 021880-003 | Jun 29, 2006 | AB | RX | Yes | No | ⤷ Try a Trial | ⤷ Try a Trial | USE OF REVLIMID (LENALIDOMIDE) FOR THE TREATMENT OF PATIENTS WITH MANTLE CELL LYMPHOMA WHOSE DISEASE HAS RELAPSED OR PROGRESSED AFTER TWO PRIOR THERAPIES, ONE OF WHICH INCLUDED BORTEZOMIB | ⤷ Try a Trial | |||
| Bristol Myers Squibb | REVLIMID | lenalidomide | CAPSULE;ORAL | 021880-006 | Jun 5, 2013 | AB | RX | Yes | No | ⤷ Try a Trial | ⤷ Try a Trial | USE OF REVLIMID (LENALIDOMIDE) FOR THE TREATMENT OF PATIENTS WITH MANTLE CELL LYMPHOMA WHOSE DISEASE HAS RELAPSED OR PROGRESSED AFTER TWO PRIOR THERAPIES, ONE OF WHICH INCLUDED BORTEZOMIB | ⤷ Try a Trial | |||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Patented / Exclusive Use | >Submissiondate |
International Family Members for US Patent 8,741,929
| Country | Patent Number | Estimated Expiration | Supplementary Protection Certificate | SPC Country | SPC Expiration |
|---|---|---|---|---|---|
| Argentina | 062265 | ⤷ Try a Trial | |||
| Austria | E486601 | ⤷ Try a Trial | |||
| Australia | 2007282027 | ⤷ Try a Trial | |||
| Canada | 2659774 | ⤷ Try a Trial | |||
| Canada | 2836006 | ⤷ Try a Trial | |||
| >Country | >Patent Number | >Estimated Expiration | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration |
